Overview

Pharmacokinetics and Safety Profile of a Single Dose GZR4 in Subjects with Renal Impairment

Status:
COMPLETED
Trial end date:
2024-09-05
Target enrollment:
Participant gender:
Summary
This study will be conducted to investigated the effect of decreased kidney function on PK and safety of GZR4 and to guide dosing recommendations in people with kidney impairment.
Phase:
PHASE1
Details
Lead Sponsor:
Gan and Lee Pharmaceuticals, USA